The two backbones of CGeneTech won new honors in the third Jinji Lake skill Invitational Competition

Categories:Company News
Author:
Origin:
Time of issue:2022-02-22
Views:0

(Summary description)During the anti epidemic campaign in Suzhou, we can see that medical work is inseparable from excellent analytical and technical personnel. Recently, good news came from the 11th high skill competition and the 3rd Jinjihu skill Invitational Competition: two technical backbones of CGeneTech's new drug R & D - Analysis Department passed all the way and won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.

The two backbones of CGeneTech won new honors in the third Jinji Lake skill Invitational Competition

(Summary description)During the anti epidemic campaign in Suzhou, we can see that medical work is inseparable from excellent analytical and technical personnel. Recently, good news came from the 11th high skill competition and the 3rd Jinjihu skill Invitational Competition: two technical backbones of CGeneTech's new drug R & D - Analysis Department passed all the way and won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.

Categories:Company News
Author:
Origin:
Time of issue:2022-02-22
Views:0

During the anti epidemic campaign in Suzhou, we can see that medical work is inseparable from excellent analytical and technical personnel. Recently, good news came from the 11th high skill competition and the 3rd Jinjihu skill Invitational Competition: two technical backbones of CGeneTech's new drug R & D - Analysis Department passed all the way and won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.

In 2021, the 11th high skill competition and the 3rd Jinji Lake skill Invitational Competition opened 22 events with the theme of "technology inherits ingenuity and creates the future". The competition closely follows the demand for skilled talents in the development of key industries and emerging industries in the park. Since its launch, it has attracted more than 6600 players, and finally 2927 people entered the finals.

High quality talent reserve is a necessary factor for enterprise innovation. Two key employees of CGeneTech's new drug R & D - Analysis Department participated in the third Jinji Lake skill Invitational Competition - "Baituo Agilent Cup" biomedical chromatographic analysis technology national open challenge. After fierce competition in the preliminary and final, they finally won the second prize in the final of biochemical pharmaceutical engineering technology (staff group) team competition.

Founded in Suzhou Industrial Park in 2010, CGeneTech is a biotechnology company committed to the research and development of small molecule drugs in the fields of hypoglycemic, antitumor and rare diseases.
Since its establishment, the company has built a rich pipeline of class 1 innovative drugs. Its self-developed Cetagliptin phosphate is a new DPP-4 inhibitor, which is in phase 3 clinical practice. It is expected that all subjects will complete phase 3 clinical practice in the middle of 2022. From the results of the subjects who completed the trial, Cetagliptin phosphate showed good safety and the effect of reducing glycosylated hemoglobin. If it reaches the end point of clinical efficacy, its approval will fill the gap of domestic production of DPP-4 inhibitors (now approved are imported and registered), and has broad market prospects.

Not long ago, CGeneTech generic telifloxamine tablets were officially approved in China. The approved indication is recurrent multiple sclerosis, which is the first domestic telifloxamine approved for listing in China. After listing, it will bring high-quality and more accessible therapeutic drugs to domestic patients.

Previous: CGeneTech was rated as the most growing innovative pharmaceutical enterprise

Next: Good news! Dr. Tong Wang, CSO of Centec and Dr. Jiahong Zhao, CMO of Centec were awarded as Gusu Leading Talents

Previous: CGeneTech was rated as the most growing innovative pharmaceutical enterprise

Next: Good news! Dr. Tong Wang, CSO of Centec and Dr. Jiahong Zhao, CMO of Centec were awarded as Gusu Leading Talents

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.

2025-04-16

Media Attention | Professor Su Qing: Based on the status quo and taking innovation as the wing, sengliptin opens a new chapter in the treatment of DPP-4 inhibitors

In recent years, the prevalence of diabetes in China has continued to rise, but the control rate is still at a low level, and more effective prevention and control measures and optimized treatment options are urgently needed. In this context, the new generation of DPP-4 inhibitor senpaliptin has been approved for marketing in China, providing a new option for the treatment of T2DM. In order to have a deeper understanding of the current status of diabetes mellitus in China, as well as the important value of DPP-4 inhibitors in hypoglycemic therapy, especially the drug characteristics and hypoglycemic efficacy of the new generation of DPP-4 inhibitor senpaglitin, we specially invited Professor Su Qing from Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine to conduct an in-depth interview to share his professional insights and valuable experience.

2025-04-15